TO ENTIRE SENATE ENDORSING
October 7, 2002
As the 107th Congress draws to a close, the cancer community urges the Congress to place a high priority on passage of the Access to Cancer Therapies Act before adjournment. While we all strongly support a comprehensive Medicare drug benefit, that goal may not be attainable this year. Therefore, we believe it is imperative that any Medicare legislative package include at least some enhancement of benefits, and no candidate is more pressing than S. 913.
Hundreds of your colleagues in the Congress have lent their support to this legislation. More than half of all Senators and more than three-quarters of House Members have signed on as co-sponsors. It is difficult to imagine a more worthy legislative option for incremental benefit enhancement.
Cancer is a disease of the elderly, and beneficiaries depend almost exclusively on the Medicare program to access quality cancer care. As cancer therapies move increasingly to oral delivery rather than provider administration, quality cancer care can only be maintained if beneficiaries have access to the new targeted therapies that remedy the specific cancer-causing defect without devastating side effects.
S. 913 will provide
immediate access to these life-saving new targeted drugs, while also relieving
breast and prostate cancer patients of the burden of paying out-of-pocket
for drugs that have long been known to improve survival and enhance quality
of life. This is
© 2001-2002 Cancer Leadership Council. All rights reserved.